UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 450

Sortiert nach

A mathematical framework for virtual IMRT QA using machine learning

Medical physics (Lancaster), 2016-07, Vol.43 (7), p.4323-4334

2016

Link zum Volltext

Verfügbarkeit prüfen

Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer

Annals of oncology, 2014-01, Vol.25 (1), p.132-138

2014

Link zum Volltext

Verfügbarkeit prüfen

Donor-Derived Metastatic Melanoma and Checkpoint Inhibition

Transplantation proceedings, 2017-09, Vol.49 (7), p.1551-1554

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II evaluation of intratumoral INT230-6 for the treatment of solid tumors

Annals of oncology, 2018-10, Vol.29, p.viii413-viii413

2018

Link zum Volltext

Verfügbarkeit prüfen

Initial safety assessment of MAGE-A4 SPEAR T-cells

Annals of oncology, 2018-10, Vol.29, p.viii412-viii412

2018

Link zum Volltext

Verfügbarkeit prüfen

SU‐E‐T‐202: Statistical Analysis of Patient's Treatment Site Specific QA Using MapCHECK2 for Local Delivery Guideline

Medical Physics, 2013-06, Vol.40 (6), p.250-250

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours

British journal of cancer, 2012-10, Vol.107 (8), p.1268-1276

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours

British journal of cancer, 2012-10, Vol.107 (8), p.1277-1285

2012

Link zum Volltext

Verfügbarkeit prüfen

First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1

Annals of oncology, 2018-10, Vol.29, p.viii404-viii404

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor

British journal of cancer, 2010-11, Vol.103 (10), p.1554-1561

2010

Link zum Volltext

Verfügbarkeit prüfen

EP-1497: High resolution air-vented ionization chamber array for QA of VMAT and stereotactic treatments

Radiotherapy and oncology, 2016-04, Vol.119, p.S691-S692

2016

Link zum Volltext

Verfügbarkeit prüfen

511 Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma

European journal of cancer (1990), 2015-09, Vol.51, p.S106-S107

2015

Link zum Volltext

Verfügbarkeit prüfen

Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study

European journal of cancer (1990), 2022-10, Vol.174, p.S125-S126

2022

Link zum Volltext

Verfügbarkeit prüfen

Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037

Annals of oncology, 2016-10, Vol.27, p.vi380-vi380

2016

Link zum Volltext

Verfügbarkeit prüfen

SU‐E‐T‐153: Establish a Comprehensive Patient‐Specific Plan QA Database for Instituitional Quality Control Program

Medical physics (Lancaster), 2014-06, Vol.41 (6Part13), p.258-258

2014

Link zum Volltext

Verfügbarkeit prüfen

Molt-4 rho(0) cells up regulate stress-induced survival genes in an attempt to overcome the potentially lethal consequence of mitochondrial DNA depletion

Clinical pharmacology and therapeutics, 2004-02, Vol.75 (2), p.P17-P17

2004

Link zum Volltext

Verfügbarkeit prüfen

SU‐E‐J‐155: Automatic Quantitative Decision Making Metric for 4DCT Image Quality

Medical physics (Lancaster), 2015-06, Vol.42 (6Part9), p.3300-3300

2015

Link zum Volltext

Verfügbarkeit prüfen

SU‐C‐BRD‐03: Closing the Loop On Virtual IMRT QA

Medical physics (Lancaster), 2015-06, Vol.42 (6Part2), p.3192-3192

2015

Link zum Volltext

Verfügbarkeit prüfen

P01.01 A Phase 1a/1b dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2020-10, Vol.8 (Suppl 2), p.A7-A8

2020

Link zum Volltext

Verfügbarkeit prüfen

OA05.02 Epacadostat Plus Pembrolizumab in Patients with Non-Small Cell Lung Cancer: Phase 1/2 Results from ECHO-202/KEYNOTE-037

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S330-S330

2018

Link zum Volltext

Verfügbarkeit prüfen

Stunning, preconditioning, and functional recovery after global myocardial ischemia

The Annals of thoracic surgery, 1994-09, Vol.58 (3), p.822-827

1994

Link zum Volltext

Verfügbarkeit prüfen

A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors

European journal of cancer (1990), 2016-12, Vol.69, p.S143-S143

2016

Link zum Volltext

Verfügbarkeit prüfen

First-in-human dose-escalation safety and PK trial of a novel humanized monoclonal CovX body dual inhibitor of angiopoietin 2 and vascular endothelial growth factor

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3055-3055

2011

Link zum Volltext

Verfügbarkeit prüfen

In vivo validation of a transit-time ultrasonic volume flow meter

Journal of Pharmacological and Toxicological Methods, 1994-06, Vol.31 (3), p.153-160

1994

Link zum Volltext

Verfügbarkeit prüfen

Enhanced myocardial protection during global ischemia with 5’-nucleotidase inhibitors

The Journal of thoracic and cardiovascular surgery, 1992-01, Vol.103 (1), p.73-77

1992

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 450

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(392)
Mit Volltextzugriff
(370)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(168)
Life Sciences & Biomedicine
(141)
Humans
(137)
Male
(79)
Adult
(70)
Female
(58)
Oncology
(58)
Middle Aged
(57)
Aged
(40)
Public, Environmental & Occupational Health
(34)
Tumors
(31)
Animals
(27)
Neoplasms - Drug Therapy
(24)
Biological And Medical Sciences
(23)
Immunotherapy
(23)
Medical Sciences
(22)
Aged, 80 And Over
(20)
Pharmacology & Pharmacy
(20)
Melanoma
(17)
Treatment Outcome
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

A mathematical framework for virtual IMRT QA using machine learning

Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer

Donor-Derived Metastatic Melanoma and Checkpoint Inhibition

Phase I/II evaluation of intratumoral INT230-6 for the treatment of solid tumors

Initial safety assessment of MAGE-A4 SPEAR T-cells

SU‐E‐T‐202: Statistical Analysis of Patient's Treatment Site Specific QA Using MapCHECK2 for Local Delivery Guideline

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours

First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1

Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor

EP-1497: High resolution air-vented ionization chamber array for QA of VMAT and stereotactic treatments

511 Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma

Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study

Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037

SU‐E‐T‐153: Establish a Comprehensive Patient‐Specific Plan QA Database for Instituitional Quality Control Program

Molt-4 rho(0) cells up regulate stress-induced survival genes in an attempt to overcome the potentially lethal consequence of mitochondrial DNA depletion

SU‐E‐J‐155: Automatic Quantitative Decision Making Metric for 4DCT Image Quality

SU‐C‐BRD‐03: Closing the Loop On Virtual IMRT QA

P01.01 A Phase 1a/1b dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors

OA05.02 Epacadostat Plus Pembrolizumab in Patients with Non-Small Cell Lung Cancer: Phase 1/2 Results from ECHO-202/KEYNOTE-037

Stunning, preconditioning, and functional recovery after global myocardial ischemia

A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors

First-in-human dose-escalation safety and PK trial of a novel humanized monoclonal CovX body dual inhibitor of angiopoietin 2 and vascular endothelial growth factor

In vivo validation of a transit-time ultrasonic volume flow meter

Enhanced myocardial protection during global ischemia with 5’-nucleotidase inhibitors

Suchergebnisse filtern